98 results about "Lactate dehydrogenases" patented technology

A system for optimising the production performance of a milk producing animal herd is provided. The system comprises a milk sampling apparatus, an analytical apparatus comprising separate equipment for analyzing compounds or parameters that in the presence of compounds indicative of the physiological or nutritional condition of the herd member, generates detectable signals, and apparatus directing a part of the milk sample (directing apparatus) to each separate equipment, which is controlled by data for the physiological and nutritional state of a herd member, so that the directing apparatus is only activated at pre-selected points in time or at pre-selected time intervals in the production and / or lactation cycles. Specific compounds are compounds indicative of mastitis, including beta-N-acetylhexosaminidase (NAGase) E.C. 3.2.1.52 and lactate dehydrogenase (LDH), protein balance, including milk urea nitrogen (MUN) and total protein, ketosis, including acetolactate, beta-hydroxybutyrate, acetone and lipids, fat and state in reproduction cycle, including a steroid or peptide hormone, e.g., progesterone. Furthermore, the system comprises equipment for signal detection to record and process the signals, equipment to store data and equipment to produce data output. Methods for optimizing the production performance of a milk producing animal herd and an apparatus therefor.

The present invention provides an aerobic coryneform bacterium transformant in which a lactate dehydrogenase gene is disrupted, and a pyruvate carboxylase gene is recombined so as to be highly expressed by a genetic engineering method. The aerobic coryneform bacterium transformant of the present invention can produce dicarboxylic acids from saccharides at a high production rate.

The present invention provides a method for producing lactic acid in a recombinant yeast cell culture using glucose as carbon source comprising a first, seed fermentation stage to produce biomass wherein the yeast is cultivated in a culture medium at a p H of 5 to 7, followed by a second, a production fermentation stage with biomass from the seed fermentation to produce lactic acid, wherein the yeast is cultivated in a culture medium at low p H using a yeast strain that is engineered to have lactate dehydrogenase (LDH) activity and optionally has decreased or knocked- out pyruvate decarboxylase (PDC) activity.

Genetically modified microorganisms having the ability to produce D(−)-lactic acid at temperatures between 30° C. and 55° C. are provided. In various embodiments, the microorganisms may have the chromosomal lactate dehydrogenase (ldh) gene and / or the chromosomal acetolactate synthase (alsS) gene inactivated. Exemplary microorganisms for use in the disclosed methods are Bacillus spp., such as Bacillus coagulans.

The invention belongs to the Chinese medicine pharmaceutical field and relates to the application of specific monomer leonurine in Chinese medicinal herb motherwort in preparing medicine combination, in particular to the application in preparing the medicine combination which cures ischemic cardiomyopathy. By the experimental research of anoxic myocardium models in vitro, the result shows that the leonurine can increase livability of ischemic myocyte, can decrease the leakage rate of lactate dehydrogenase, can increase the activity of antioxidase catalase, can increase the activity of SOD, can minish the level of lipid peroxidation products, and proves that the leonurine has obvious protective effect on ischemic myocardium and prepares the medicine which cures ischemic cardiomyopathy.

This invention provides a polynucleotide that encodes a protein having lactate dehydrogenase activity and such protein that can be used for producing D-lactic acid. This polynucleotide has the nucleotide sequence as shown in SEQ ID NO: 1 (a), and it hybridizes under stringent conditions with a probe comprising all or part of the nucleotide sequence as shown in SEQ ID NO: 1 or a complementary strand thereof and encodes a protein having D-lactate dehydrogenase activity (b).

The present disclosure pertains to a genetically modified microorganism that satisfies some of specific requirements. The specific requirements include: (I) compared to a wild type microorganism, having reduced or inactivated succinate dehydrogenase activity or fumarate reductase activity; (II) compared to a wild type microorganism, having reduced or inactivated lactate dehydrogenase activity; (III) having a modified phosphoenolpyruvate carboxylase activity and thus showing resistance against the feedback inhibition by aspartic acid in wild type phosphoenolpyruvate carboxylase activity, or having an exogenous phosphoenolpyruvate carboxylase activity and thus showing higher resistance against the feedback inhibition by aspartic acid than wild type phosphoenolpyruvate carboxylase activity shown by a wild type microorganism; and (IV) compared to a wild type microorganism, having reduced or inactivated pyruvate : quinone oxidoreductase.